BR0009737A - Composição farmacêutica, kit farmacêutico com um ou mais recipientes, métodos para a proteção de um mamìfero de uma patologia resultante de lesão de tecido excitável, para a intensificação da função de um tecido excitável normal ou anormal em um mamìfero, e para a facilitação da transcitose de uma molécula através de uma barreira celular endotelial em um mamìfero, e, composição para transporte de uma molécula via transcinose através de uma barreira celular endotelial - Google Patents

Composição farmacêutica, kit farmacêutico com um ou mais recipientes, métodos para a proteção de um mamìfero de uma patologia resultante de lesão de tecido excitável, para a intensificação da função de um tecido excitável normal ou anormal em um mamìfero, e para a facilitação da transcitose de uma molécula através de uma barreira celular endotelial em um mamìfero, e, composição para transporte de uma molécula via transcinose através de uma barreira celular endotelial

Info

Publication number
BR0009737A
BR0009737A BR0009737-3A BR0009737A BR0009737A BR 0009737 A BR0009737 A BR 0009737A BR 0009737 A BR0009737 A BR 0009737A BR 0009737 A BR0009737 A BR 0009737A
Authority
BR
Brazil
Prior art keywords
mammal
endothelial cell
function
cell barrier
methods
Prior art date
Application number
BR0009737-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael Brines
Anthony Cerami
Carla Cerami
Original Assignee
Kenneth S Warren Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth S Warren Lab filed Critical Kenneth S Warren Lab
Publication of BR0009737A publication Critical patent/BR0009737A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0009737-3A 1999-04-13 2000-04-13 Composição farmacêutica, kit farmacêutico com um ou mais recipientes, métodos para a proteção de um mamìfero de uma patologia resultante de lesão de tecido excitável, para a intensificação da função de um tecido excitável normal ou anormal em um mamìfero, e para a facilitação da transcitose de uma molécula através de uma barreira celular endotelial em um mamìfero, e, composição para transporte de uma molécula via transcinose através de uma barreira celular endotelial BR0009737A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29093899A 1999-04-13 1999-04-13
US54722000A 2000-04-11 2000-04-11
PCT/US2000/010019 WO2000061164A1 (en) 1999-04-13 2000-04-13 Modulation of excitable tissue function by peripherally administered erythropoietin

Publications (1)

Publication Number Publication Date
BR0009737A true BR0009737A (pt) 2003-01-14

Family

ID=26966493

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009737-3A BR0009737A (pt) 1999-04-13 2000-04-13 Composição farmacêutica, kit farmacêutico com um ou mais recipientes, métodos para a proteção de um mamìfero de uma patologia resultante de lesão de tecido excitável, para a intensificação da função de um tecido excitável normal ou anormal em um mamìfero, e para a facilitação da transcitose de uma molécula através de uma barreira celular endotelial em um mamìfero, e, composição para transporte de uma molécula via transcinose através de uma barreira celular endotelial

Country Status (21)

Country Link
EP (1) EP1171147A4 (ko)
JP (1) JP2003520194A (ko)
KR (2) KR100883232B1 (ko)
CN (1) CN1607957B (ko)
AU (1) AU784550B2 (ko)
BG (1) BG65353B1 (ko)
BR (1) BR0009737A (ko)
CA (1) CA2383940A1 (ko)
CR (1) CR6501A (ko)
CZ (1) CZ20013695A3 (ko)
EA (1) EA004766B1 (ko)
HU (1) HUP0201598A3 (ko)
IL (2) IL145895A0 (ko)
IS (1) IS6104A (ko)
MX (1) MXPA01010177A (ko)
NO (1) NO20014991L (ko)
NZ (4) NZ545478A (ko)
PL (1) PL352223A1 (ko)
SK (1) SK14412001A3 (ko)
TR (2) TR200103785T2 (ko)
WO (1) WO2000061164A1 (ko)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
WO2003089468A1 (en) * 2002-04-19 2003-10-30 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
AU2001267882A1 (en) 2000-06-30 2002-01-14 Chugai Seiyaku Kabushiki Kaisha Preventives and remedies for diseases in association with demyelination
DE10043457A1 (de) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
EP1471871B1 (en) * 2001-02-02 2007-05-02 Ortho-McNeil Pharmaceutical, Inc. Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
US20030118630A1 (en) * 2001-12-07 2003-06-26 Anthony Cerami Immune modulation device for use in animals
ATE542904T1 (de) 2001-10-29 2012-02-15 Crucell Holland Bv Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen
EP1465987B1 (en) 2001-12-07 2008-01-23 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
AU2003206251B2 (en) * 2002-01-09 2008-03-13 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
GB0211578D0 (en) * 2002-05-21 2002-06-26 Univ Belfast Medicaments
CA2491567A1 (en) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
WO2004087063A2 (en) * 2003-03-27 2004-10-14 Janssen Pharmaceutica Nv Use of erythropoietin in stroke recovery
US7718363B2 (en) * 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
WO2004099396A1 (en) 2003-05-09 2004-11-18 Crucell Holland B.V. Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
DE102004063927A1 (de) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
AT500929B1 (de) 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
CA2618396C (en) * 2005-08-05 2018-02-27 Warren Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
GB0525540D0 (en) * 2005-12-15 2006-01-25 Isis Innovation New treatment
DE102006004008A1 (de) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
CN101062407A (zh) * 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 促红细胞生成素在预防或治疗视网膜损伤中的用途
US8133860B2 (en) * 2006-07-20 2012-03-13 Rosalind Franklin University Of Medicine And Science Facilitation of resuscitation from cardiac arrest by erythropoietin
EP2101808A4 (en) * 2007-01-10 2011-11-30 Edison Pharmaceuticals Inc TREATMENT OF BREATHLY TROUBLES USING COMPOUNDS OF ERYTHROPOIETIN OR THROMBOPOIETIN ACTIVITY
WO2009010107A1 (en) * 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
JP5542064B2 (ja) 2008-01-22 2014-07-09 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体
RU2519695C2 (ru) * 2010-07-21 2014-06-20 Олег Ильич Эпштейн Лекарственное средство для лечения синдрома дефицита внимания и способ лечения синдрома дефицита внимания
CN111066727B (zh) * 2019-12-20 2021-08-27 中国人民解放军陆军军医大学 在低氧性血睾屏障通透中作用机制的小鼠模型构建方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen

Also Published As

Publication number Publication date
BG65353B1 (bg) 2008-03-31
NZ514690A (en) 2004-07-30
KR101012932B1 (ko) 2011-02-08
KR20070094997A (ko) 2007-09-27
NZ533098A (en) 2006-04-28
HUP0201598A2 (en) 2002-09-28
NO20014991L (no) 2001-11-15
TR200103785T2 (tr) 2002-06-21
WO2000061164A1 (en) 2000-10-19
BG106058A (en) 2002-12-29
KR100883232B1 (ko) 2009-02-10
CZ20013695A3 (cs) 2002-02-13
EA004766B1 (ru) 2004-08-26
CA2383940A1 (en) 2000-10-19
EP1171147A1 (en) 2002-01-16
IL145895A (en) 2010-05-31
HUP0201598A3 (en) 2002-10-28
JP2003520194A (ja) 2003-07-02
SK14412001A3 (sk) 2002-03-05
MXPA01010177A (es) 2004-09-10
AU4348700A (en) 2000-11-14
NZ560696A (en) 2010-03-26
CN1607957A (zh) 2005-04-20
EP1171147A4 (en) 2003-05-14
NZ545478A (en) 2008-04-30
IS6104A (is) 2001-10-11
PL352223A1 (en) 2003-08-11
TR200402194T2 (tr) 2004-10-21
KR20020000874A (ko) 2002-01-05
AU784550B2 (en) 2006-05-04
NO20014991D0 (no) 2001-10-12
IL145895A0 (en) 2002-07-25
CR6501A (es) 2004-04-15
CN1607957B (zh) 2012-10-10
EA200101073A1 (ru) 2002-10-31

Similar Documents

Publication Publication Date Title
BR0009737A (pt) Composição farmacêutica, kit farmacêutico com um ou mais recipientes, métodos para a proteção de um mamìfero de uma patologia resultante de lesão de tecido excitável, para a intensificação da função de um tecido excitável normal ou anormal em um mamìfero, e para a facilitação da transcitose de uma molécula através de uma barreira celular endotelial em um mamìfero, e, composição para transporte de uma molécula via transcinose através de uma barreira celular endotelial
Adhihetty et al. Effect of denervation on mitochondrially mediated apoptosis in skeletal muscle
BR9811818A (pt) Uso de um composto, composto, e, composição farmacêutica
BR9916980A (pt) Derivados bicìclicos substituìdos úteis como agentes anticancerìgenos
BRPI9914741A (pt) n-(2-aril-proprionil)-sulfonamidas, usos e composições farmacêuticas contendo as mesmas.
BR9906013A (pt) Derivados bicìclicos heteroaromáticos úteis como agentes anticancerìgenos
ES2188595T3 (es) Derivados del acido 1-(2-oxo-acetil)-piperidin-2-carboxilico como sensibilizadores de celulas cancerosas resistentes a multiples farmacos.
TR200100588T2 (tr) Hücre yapışmasının önlenmesini modüle eden aza-bisikleler.
DK1697370T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
DE69226369D1 (de) System mit erhöhender Hautpenetration für verbesserte topische Verabreichung von Arzneimitteln
ATE251140T1 (de) N-(2 oxoacetyl oder sulphonyl)- pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
BR9714677A (pt) "enantiÈmeros 3-piridila e seu uso como analgésicos"
ATE314067T1 (de) Cannabinol-11-säurederivate als entzündungshemmer und analgetika
BR9915610A (pt) Preparações farmacêuticas combinadas
EP3329913B1 (en) Composition for inhibiting formation of snare complex, containing myricetin derivatives
BR9908301A (pt) Derivados de indol e composições farmacêuticas que compreendem os mesmos
Stavisky et al. Melatonin enhances the in vitro and in vivo repair of severed rat sciatic axons
BR9915951A (pt) Processo para preparação de uma composição farmacêutica para uso como um medicamento antiarritmias com um bloqueio beta adrenérgico controlado, composição farmacêutica, preparação oral e parenteral para tratamento de doenças cardìacas em mamìferos, e, método de tratamento para as mesmas
Akyol et al. In vitro and in vivo neuroprotective effect of caffeic acid phenethyl ester
BR9712128A (pt) Métodos e composições para lipidização de moléculas hidrofìlicas
AR008095A1 (es) Indanilidinacetilguanidinas sustituidas, procedimiento para su preparacion, su uso en la preparacion de medicamentos o agentes de diagnosticoasi como medicamento que las contienen
ES2146348T3 (es) Cromanilsulfonil(tio)ureas sustituidas, procedimiento para su preparacion y su utilizacion en preparados farmaceuticos, asi como preparados farmaceuticos que las contienen.
TR199700508A2 (xx) Orto-ikame edilmi� benzoilguanidin'leri, bunlar�n imal edilmesine mahsus usul, bunlar�n ila� ya da diyagnoz maddesi olarak kullan�lmalar� ve ayr�ca bunlar� ihtiva eden ila�lar.
ATE190316T1 (de) Peptid-aldehydderivate als antikoagulierende mittel
UY26485A1 (es) "pirroles sustituidos"

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10, 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.